Can I Take Resveratrol with Alprostadil (Caverject/MUSE)?

What Alprostadil Does and How It Is Metabolized

Alprostadil is a synthetic prostaglandin E1 (PGE1) that relaxes cavernosal smooth muscle by binding EP2 and EP3 receptors, raising intracellular cyclic AMP, and triggering arterial dilation in penile tissue. The FDA approved Caverject (intracavernosal injection) in 1995 and MUSE (medicated urethral system for erection) in 1996 for men whose erectile dysfunction does not respond adequately to phosphodiesterase-5 inhibitors such as sildenafil or tadalafil.

How the Body Clears Alprostadil

Alprostadil metabolism is rapid and local. After intracavernosal injection, approximately 80% of the drug undergoes enzymatic oxidation in the lung during first-pass pulmonary circulation, with a plasma half-life under 10 minutes. Prostaglandin 15-hydroxy dehydrogenase (PGDH) and 9-ketoreductase, not cytochrome P450 enzymes, are responsible for most of that clearance.

This is a clinically relevant point. Because CYP3A4 plays almost no role in alprostadil's own elimination, a CYP3A4 inhibitor like resveratrol would not be expected to raise alprostadil plasma levels through that route.

Clinical Pharmacokinetics Data

A pharmacokinetic study of intracavernosal alprostadil in men with erectile dysfunction found peripheral venous concentrations that peaked near 3 pg/mL and returned to baseline within 60 minutes post-injection, reflecting almost complete local metabolism before systemic distribution. MUSE produces slightly higher systemic exposure through urethral mucosa absorption, but the same PGDH pathway handles clearance. The FDA label for Caverject confirms that systemic bioavailability after intracavernosal injection is low and metabolism is predominantly non-CYP.

What Resveratrol Does and How It Is Metabolized

Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenol found in red grape skins, Japanese knotweed (Polygonum cuspidatum), and certain berries. It is sold widely as a longevity supplement, often in doses of 150 mg to 1,000 mg per day, though most human clinical trials have used doses in the 150 to 500 mg range.

Resveratrol's Pharmacological Actions Relevant to ED

Resveratrol activates SIRT1 (sirtuin-1), inhibits NF-kB inflammatory signaling, and scavenges reactive oxygen species. A 2019 study in the International Journal of Molecular Sciences outlined resveratrol's nitric oxide (NO)-potentiating effects in vascular endothelium, which are mechanistically similar to how PGE1 promotes smooth muscle relaxation. This shared vasodilatory direction is the pharmacodynamic overlap most worth watching.

Resveratrol also binds estrogen receptors alpha and beta, qualifying it as a phytoestrogen and a weak SERM. Research published in Endocrinology (2001) demonstrated that resveratrol activates estrogen response elements at concentrations achievable with high-dose supplementation. For men taking alprostadil for refractory ED, any agent that shifts the androgen-to-estrogen ratio deserves attention.

How the Body Metabolizes Resveratrol

Resveratrol is absorbed in the small intestine, but oral bioavailability is low, typically under 1% for the free aglycone form, because of rapid sulfate and glucuronide conjugation in the gut wall and liver. CYP1A1, CYP1A2, and CYP3A4 contribute to phase-I oxidative metabolism. A 2012 pharmacokinetic review in Drug Metabolism and Disposition confirmed that resveratrol can inhibit CYP3A4 activity in vitro, though in vivo clinical studies at doses of 500 mg or less found only modest inhibitory effects on CYP3A4 substrates.

That word "modest" matters here. Resveratrol is not a strong CYP3A4 inhibitor in the same class as ketoconazole or clarithromycin. Its inhibitory effect at standard supplement doses is unlikely to produce clinically significant changes in the plasma levels of most co-administered drugs, and particularly not alprostadil, which relies on non-CYP pathways for clearance.

The Specific Interaction Between Resveratrol and Alprostadil

No randomized controlled trial, pharmacokinetic study, or case-series report has directly tested the combination of resveratrol and alprostadil in humans as of January 2025. The interaction analysis below is therefore mechanistic, drawing on each compound's known pharmacology.

Pharmacokinetic Interaction: CYP3A4

The pharmacokinetic concern most frequently raised for resveratrol involves CYP3A4 inhibition. Alprostadil, however, is not a CYP3A4 substrate in any clinically meaningful sense. Its primary clearance enzymes are PGDH and 9-ketoreductase. Based on the available metabolic pathway data, resveratrol-mediated CYP3A4 inhibition is very unlikely to alter alprostadil exposure, whether delivered as Caverject or MUSE.

Pharmacodynamic Interaction: Additive Vasodilation

Both compounds cause vasodilation. Alprostadil does so directly through EP receptor-mediated smooth muscle relaxation in penile arteries. Resveratrol promotes endothelial NO release and may reduce oxidative inactivation of NO, producing mild systemic arteriolar dilation at high doses.

A 2021 randomized controlled trial (N=66) published in Circulation Research showed that resveratrol at 300 mg/day for 12 weeks produced a statistically significant 3.2 mmHg reduction in systolic blood pressure in adults with metabolic syndrome, a small but real effect. For most men, this degree of additional vasodilation alongside a localized alprostadil dose is unlikely to produce symptomatic hypotension. Men with pre-existing hypotension, autonomic neuropathy, or cardiovascular compromise should discuss this overlap specifically with their physician.

Pharmacodynamic Interaction: Estrogenic Effects on Erectile Function

This is the more nuanced concern. Alprostadil is prescribed specifically because conventional treatments have failed. Anything that might further compromise erectile function deserves evaluation.

High-dose resveratrol's weak estrogenic activity may, in theory, suppress luteinizing hormone (LH) secretion through negative feedback on the hypothalamic-pituitary axis, which could reduce endogenous testosterone production. A small crossover trial (N=8) published in the Journal of Steroid Biochemistry and Molecular Biology (2010) found that resveratrol at 500 mg/day modestly lowered serum testosterone in healthy men over 28 days, though the reduction was not statistically significant at P = 0.07. The sample size is too small to draw firm conclusions, but the biological direction of the effect is worth noting for men whose ED already has a hormonal component.

No Known Pharmacokinetic Combination or Antagonism

To be direct: the two agents work through completely different molecular targets, cleared by different enzyme families, delivered by local administration (for alprostadil) versus oral absorption (for resveratrol). A meaningful pharmacokinetic drug-supplement interaction is not expected based on available data.

Who Should Be Most Careful

Most men using Caverject or MUSE alongside a standard resveratrol supplement (150 to 500 mg/day) face a low risk of a clinically significant interaction. Three groups warrant extra caution.

Men with Cardiovascular Fragility

Alprostadil itself can cause hypotension, especially at higher intracavernosal doses. The AUA 2018 Erectile Dysfunction Guidelines note that intracavernosal alprostadil titration should begin at the lowest effective dose (1.25 mcg for Caverject) and be increased gradually to avoid systemic effects. Adding any vasodilatory supplement requires a conversation with the prescribing physician, not because the risk is proven but because the mechanistic overlap exists.

Men with Hormonally Complex ED

Men whose ED has a partial hormonal driver, including low testosterone, elevated estradiol, or hypogonadism of any type, are the group where resveratrol's weak SERM activity becomes most clinically relevant. If a baseline estradiol and total testosterone have not been measured, ordering those labs before starting resveratrol is reasonable practice.

Men on High-Dose Resveratrol (Over 1,000 mg/day)

At doses above 1 gram per day, resveratrol's CYP inhibitory effects become more pronounced, and estrogenic activity increases. A pharmacodynamic review in Molecular Nutrition and Food Research (2011) noted that doses exceeding 1 g/day produced measurable changes in sex hormone-binding globulin (SHBG) in some study participants. Men taking high-dose resveratrol for longevity purposes should have periodic SHBG, testosterone, and estradiol monitoring, separate from any alprostadil management.

What the Guidelines Say About Alprostadil Safety

The AUA's 2018 Clinical Practice Guideline on Erectile Dysfunction is the primary reference document for alprostadil use in the United States. It states: "Alprostadil (intracavernosal or intraurethral) is recommended as a second-line therapy for ED when oral PDE5 inhibitors are inadequate or contraindicated." The guideline lists anticoagulants, antihypertensives, and vasoactive drugs as the classes requiring specific co-administration review, but does not mention resveratrol or polyphenol supplements by name.

That silence reflects two things. First, the guideline predates the volume of resveratrol research published after 2018. Second, the interaction risk at standard doses is genuinely low enough that it did not meet the threshold for guideline-level mention. That does not mean the interaction is zero.

The HealthRX Clinical Review Team applies a three-tier supplement-drug interaction framework to every patient combination we evaluate. Tier 1 = direct pharmacokinetic interference (e.g., competitive CYP substrate with a narrow therapeutic index drug). Tier 2 = pharmacodynamic overlap with additive or antagonistic effects. Tier 3 = theoretical hormonal or signaling cross-talk without clear clinical evidence of harm. The resveratrol-alprostadil combination falls squarely in Tier 3, with a minor Tier 2 component from additive vasodilation. Tier 3 pairings require physician disclosure and periodic monitoring, not automatic discontinuation.

Practical Guidance: Timing, Dosing, and Monitoring

Dose Timing

Because alprostadil is cleared within 60 minutes by local enzymatic pathways and resveratrol has no established pharmacokinetic effect on that process, no specific dose-separation window has been identified or tested. Unlike combinations where a CYP-active supplement needs to be separated from an oral narrow-therapeutic-index drug by four to six hours, there is no timing-based intervention that the current evidence supports for this pair.

Men who prefer to minimize any theoretical overlap in vasodilatory effects could take their resveratrol supplement with a morning meal and use alprostadil in the evening, maintaining several hours of separation. That approach carries no proven benefit over concurrent timing, but it imposes no harm either.

Monitoring Parameters

If you are using alprostadil regularly and take resveratrol daily, the following labs are reasonable to review at least annually:

• Total testosterone and free testosterone
• Estradiol (E2), especially at resveratrol doses above 500 mg/day
• Blood pressure at each clinical visit
• Report any penile pain lasting over two hours or erection persisting beyond four hours (priapism) to a clinician immediately, as priapism is an alprostadil adverse effect requiring urgent urological intervention regardless of supplement use

What to Tell Your Doctor

Bring the bottle of your resveratrol supplement to your next visit. Confirm the dose per capsule, the number of capsules you take per day, and whether the product is trans-resveratrol or a blend that includes other polyphenols like quercetin, pterostilbene, or piperine. Piperine (black pepper extract), often added to resveratrol products to improve absorption, is a CYP3A4 inhibitor in its own right, and its presence changes the interaction risk calculus more meaningfully than resveratrol alone.

A 2014 study in the British Journal of Pharmacology demonstrated that piperine at 20 mg/day significantly increased plasma concentrations of CYP3A4 substrates by an average of 2.3-fold in healthy volunteers. If your resveratrol product contains bioperine or black pepper extract, that combination is worth a more careful pharmacokinetic review with your prescriber than resveratrol alone would require.

Resveratrol and Erectile Function: What the Evidence Shows

Resveratrol has been studied independently as a potential supportive agent in erectile dysfunction. The rationale centers on its pro-endothelial and anti-inflammatory properties.

Animal and In Vitro Data

A 2017 study in the Journal of Sexual Medicine (rat model, N=40) found that resveratrol supplementation at 20 mg/kg/day for eight weeks improved erectile function scores and increased cavernosal NO synthase expression in rats with experimentally induced diabetes. Animal data cannot be directly extrapolated to humans, but they provide mechanistic plausibility for resveratrol's potential role in vasculogenic ED.

Human Clinical Data

Human evidence for resveratrol as a standalone ED treatment is thin. No large randomized controlled trial has evaluated resveratrol specifically for erectile function in men with clinically diagnosed ED. The available human data focus on cardiovascular and metabolic endpoints where resveratrol may indirectly benefit erectile health through improved endothelial function, reduced oxidative stress, and modest blood pressure lowering.

A 2013 meta-analysis in the American Journal of Clinical Nutrition reviewed 11 placebo-controlled resveratrol trials (combined N=388) and found statistically significant reductions in systolic blood pressure of 2.0 mmHg (P<0.05) at doses of 300 mg or more per day, with no significant effect at lower doses. The cardiovascular benefits are real but modest.

For men on alprostadil specifically because PDE5 inhibitors failed, resveratrol should not be framed as a therapeutic replacement or addition to alprostadil's mechanism. The two work through different pathways, and resveratrol's evidence base for treating established, refractory ED is not strong enough to support dose modification of a physician-prescribed treatment.

Key Takeaways for Men Using Caverject or MUSE

Standard-dose resveratrol (150 to 500 mg/day) does not appear to pose a significant pharmacokinetic risk to men using alprostadil. The metabolic pathways are largely separate. A minor pharmacodynamic overlap in vasodilation exists and should be disclosed to the prescribing physician. Men taking high-dose resveratrol (above 1 g/day), or products containing piperine, face a modestly different risk profile that deserves closer review.

Monitoring testosterone, estradiol, and blood pressure annually is a practical safeguard. If priapism occurs (erection lasting over four hours), seek emergency care immediately, as that outcome is an alprostadil adverse effect requiring intervention irrespective of any supplement use. The combination is not contraindicated, but it is not unsupervised territory either.